glp 1 research Discovery of GLP-1–Based Drugs for the Treatment of Obesity Researchers at UC Irvine issue
Description
For in-vitro laboratory research only
10.2337/diab.43.4.535
If hormonal deficiency was also a factor, that underlying issue would still need to be addressed separately
Phase 3 REDEFINE trials confirmed 50% greater weight loss compared to semaglutide alone, with 43% of participants achieving over 20% body weight loss
doi: 10.2337/db08-1651
